Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features

被引:25
作者
Horie, S [1 ]
Maeta, H [1 ]
Endo, K [1 ]
Ueta, T [1 ]
Takashima, K [1 ]
Terada, T [1 ]
机构
[1] Tottori Univ, Fac Med, Dept Pathol 2, Yonago, Tottori 6838503, Japan
关键词
immunohistochemistry; MDM2; neoplasms; p53; papillary carcinoma of the thyroid;
D O I
10.1046/j.1440-1827.2001.01159.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Expression of p53 protein and MDM2 was evaluated in paraffin-embedded tissue from 78 patients with papillary carcinomas of the thyroid (PCT), in order to elucidate the relationship between them and their correlations with some clinicopathologic features implicated in tumor progression. These proteins were expressed in nuclei of tumor cells, but not in non-tumor cells. Staining was defined as positive when 10% or more of tumor cells expressed these proteins. The number of cases positive for p53 protein was 21/78 (27%), and that positive for MDM2 was 26/78 (33%). Co-overexpression of p53 protein and MDM2 was observed in 12/78 cases (15%). A significant positive relationship was found between them (P < 0.01); p53-positive cases tended to be also positive for MDM2 and vice versa. Statistical analysis revealed that overexpression of p53 protein significantly correlated with large tumor size (P = 0.0271) and the presence of capsular invasion (P = 0.04). There were significant positive correlations between tumor size and intrathyroidal invasion and between tumor size and capsular invasion in PCT, suggesting that p53 protein overexpression is associated only with tumor progression (tumor size). However, we could not find any significant correlations between MDM2 expression and clinicopathologic features. Our findings suggest that overexpression of p53 protein and MDM2 in papillary carcinoma of the thyroid is associated with the progression of the tumors, and that p53 may be a marker of the progression of PCT.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 32 条
  • [1] CADY B, 1988, SURGERY, V104, P947
  • [2] Chen BK, 1999, INT J ONCOL, V15, P893
  • [3] REGULATION OF TRANSCRIPTION FUNCTIONS OF THE P53 TUMOR-SUPPRESSOR BY THE MDM-2 ONCOGENE
    CHEN, JD
    LIN, JY
    LEVINE, AJ
    [J]. MOLECULAR MEDICINE, 1995, 1 (02) : 142 - 152
  • [4] OVEREXPRESSION OF P53 AS A POSSIBLE PROGNOSTIC FACTOR IN HUMAN THYROID-CARCINOMA
    DOBASHI, Y
    SAKAMOTO, A
    SUGIMURA, H
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) : 375 - 381
  • [5] GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND
    DONGHI, R
    LONGONI, A
    PILOTTI, S
    MICHIELI, P
    DELLAPORTA, G
    PIEROTTI, MA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) : 1753 - 1760
  • [6] FRITSCHE, 1993, ONCOGENE, V8, P2605
  • [7] Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis
    Godballe, C
    Asschenfeldt, P
    Jorgensen, KE
    Bastholt, L
    Clausen, PP
    Hansen, TP
    Hansen, O
    Bentzen, SM
    [J]. LARYNGOSCOPE, 1998, 108 (02) : 243 - 249
  • [8] p53 in growth control and neoplasia
    Gottlieb, TM
    Oren, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (2-3): : 77 - 102
  • [9] HANNEQUIN P, 1986, CANCER, V58, P1749
  • [10] HAY ID, 1993, SURGERY, V114, P1050